Why 3SBio’s NUMABODY infliximab stands out in chronic autoimmune care

Reviewed: ad hoc news Software & Services desk. Edited and checked on 2026-06-18, 13:17. Details in the imprint.

With NUMABODY infliximab, 3SBio puts a clear, pale lyophilized cake in a small vial that decides whether a rheumatoid arthritis flare calms down or not. Nurses see a predictable infusion, rheumatologists a familiar mechanism, patients a chance at quieter joints.

What NUMABODY infliximab targets

NUMABODY infliximab is a biosimilar to the well-known anti-TNF monoclonal antibody infliximab, targeting autoimmune conditions such as rheumatoid arthritis, ankylosing spondylitis, psoriasis and inflammatory bowel disease in suitable patients.

The drug binds tumor necrosis factor alpha, a central inflammatory cytokine, and is given as an intravenous infusion at defined intervals under specialist supervision in hospital or outpatient infusion centers.

Formulation and handling in practice

3SBio offers NUMABODY infliximab as a lyophilized powder in a vial that is reconstituted with sterile water and further diluted into an infusion bag, a routine pharmacists and nurses know from reference infliximab.

Each vial is formulated for a fixed infliximab content, so staff dose by body weight and line up several vials per patient, which looks a bit like assembling small glass soldiers before the drip starts.

Dosing pattern and infusion experience

Patients usually start with induction doses at weeks 0, 2 and 6, then continue with maintenance infusions roughly every 8 weeks, depending on indication and physician judgment.

The infusion itself takes at least 2 hours, often longer at the beginning, as staff monitor for infusion reactions with blood pressure cuffs, pulse oximeters and a prepared emergency tray in the corner.

Safety, monitoring and biosimilar trust

As with the reference, NUMABODY infliximab carries risks such as infusion reactions, infections and rare serious adverse events, so regular lab checks, tuberculosis screening and vaccination status reviews are part of the treatment routine.

For clinicians, the key is consistent quality and pharmacovigilance data that show the biosimilar behaves as expected, so switching from originator infliximab can be done with confidence when payers or hospital tenders favor the 3SBio product.

Position in 3SBio’s portfolio and stock angle

For 3SBio, NUMABODY infliximab complements a broader biologics and biosimilars pipeline in oncology, nephrology and autoimmune disease, helping the group defend share as more reference biologics lose exclusivity.

Shares of 3SBio Inc (HK1530013386) trade in Hong Kong on the HKEX, giving investors direct exposure to the company’s Chinese biologics and biosimilars strategy.

This article was AI-assisted and editorially reviewed. Product information without guarantee; prices and availability may change at short notice. No investment advice, no buy or sell recommendation. Stock-market transactions involve risks up to total loss.